Dianthus Therapeutics (NASDAQ:DNTH) Stock Price Expected to Rise, Jefferies Financial Group Analyst Says

Dianthus Therapeutics (NASDAQ:DNTH) had its price target upped by equities research analysts at Jefferies Financial Group from $66.00 to $81.00 in a research note issued to investors on Monday,Benzinga reports. The brokerage currently has a “buy” rating on the stock. Jefferies Financial Group’s price target indicates a potential upside of 54.40% from the company’s previous close.

Several other research analysts have also recently issued reports on DNTH. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, January 21st. HC Wainwright upped their target price on Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Wedbush reissued an “outperform” rating and set a $46.00 price target on shares of Dianthus Therapeutics in a research report on Monday, December 22nd. Finally, Truist Financial raised their price target on Dianthus Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a research note on Thursday, January 8th. Nine analysts have rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat.com, the stock currently has an average rating of “Moderate Buy” and a consensus price target of $66.50.

Dianthus Therapeutics Price Performance

DNTH stock opened at $52.46 on Monday. Dianthus Therapeutics has a 12 month low of $13.36 and a 12 month high of $57.50. The firm’s 50-day moving average is $44.14 and its 200 day moving average is $35.70. The company has a market capitalization of $2.27 billion, a PE ratio of -15.07 and a beta of 1.59.

Dianthus Therapeutics (NASDAQ:DNTH) last released its quarterly earnings data on Wednesday, November 5th. The company reported ($0.97) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.86) by ($0.11). The company had revenue of $0.40 million during the quarter, compared to analysts’ expectations of $0.58 million. Dianthus Therapeutics had a negative net margin of 4,106.04% and a negative return on equity of 33.02%. Sell-side analysts forecast that Dianthus Therapeutics will post -2.61 EPS for the current fiscal year.

Insiders Place Their Bets

In related news, EVP Simrat Randhawa sold 109,031 shares of the firm’s stock in a transaction dated Friday, November 14th. The stock was sold at an average price of $38.14, for a total transaction of $4,158,442.34. Following the sale, the executive vice president owned 4,000 shares of the company’s stock, valued at $152,560. This trade represents a 96.46% decrease in their ownership of the stock. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this link. Also, CFO Ryan Savitz sold 20,000 shares of the business’s stock in a transaction dated Thursday, December 4th. The stock was sold at an average price of $45.18, for a total transaction of $903,600.00. The disclosure for this sale is available in the SEC filing. Insiders have sold a total of 216,538 shares of company stock valued at $8,283,175 over the last 90 days. 16.56% of the stock is currently owned by company insiders.

Institutional Investors Weigh In On Dianthus Therapeutics

A number of hedge funds and other institutional investors have recently bought and sold shares of DNTH. UBS Group AG grew its holdings in Dianthus Therapeutics by 342.6% in the fourth quarter. UBS Group AG now owns 606,620 shares of the company’s stock worth $24,999,000 after purchasing an additional 469,547 shares during the last quarter. Vanguard Group Inc. boosted its position in shares of Dianthus Therapeutics by 24.7% in the 4th quarter. Vanguard Group Inc. now owns 2,048,452 shares of the company’s stock worth $84,417,000 after purchasing an additional 406,254 shares in the last quarter. Zurcher Kantonalbank Zurich Cantonalbank acquired a new stake in shares of Dianthus Therapeutics in the 4th quarter worth $135,000. Palumbo Wealth Management LLC grew its stake in Dianthus Therapeutics by 125.1% during the 4th quarter. Palumbo Wealth Management LLC now owns 14,967 shares of the company’s stock worth $617,000 after buying an additional 8,317 shares during the last quarter. Finally, SG Americas Securities LLC acquired a new position in Dianthus Therapeutics during the 4th quarter valued at about $765,000. Hedge funds and other institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.